1. Number of studies assessing each primary outcome.
| Primary outcomes | n trials reporting (n participants) | n trials NOT reporting (n participants) |
| All‐cause mortality | 39 (17,586) | 3a (393) |
| Cardiovascular mortality | Same as total mortality | Same as total mortality |
| Stroke | 11 (9139) | 30 (8840) |
| Adverse effects (proarrhythmia and withdrawals due to adverse effects) | 39 (16,558) | 3b (1421) |
Out of 41 studies comparing an active drug with a control group receiving no antiarrhythmic (total 17,979 participants).
aChun 2014; DAPHNE 2008; Santas 2012.
bAFIB 1997; Chun 2014; Santas 2012. Others studies did not reported proarrhythmia but reported withdrawals (DAPHNE 2008; Niu 2006; Villani 1992).